

Quarterly Activities Report and Appendix 4C

Bio-Gene Technology Limited (**ASX:BGT**, “**Bio-Gene**” or “**the Company**”), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides an update on activities for the quarter ended 30 September 2026 (Q1 FY27), and to date.

Q1 FY27 Highlights

- **Documentation and product development activities are in progress to support the first commercial supply of Qcide to Japan**
- **16th Qcide[®] harvest was completed at the north Queensland plantation**
- **Draft preliminary reports for the OECD 424 and OECD 443 toxicity studies are currently undergoing scientific and technical review prior to finalisation and release of the results**
- **Bio-Gene’s MD/CEO attended major meetings in Japan and the US**
- **Subsequent to quarter end, Flavocide[®] tick efficacy data was published in the peer-reviewed journal Ticks and Tick-borne Diseases**
- **Grants and allowances were obtained for Flavocide patent families encompassing its use in combinations, to control resistant pests, and for control of aphids**
- **Completed the second tranche of the Placement and SPP underwriting, bringing total gross proceeds from the Placement and SPP to approximately \$3.275 million**
- **Received a \$343,000 R&D tax incentive subsequent to quarter end, relating to eligible FY26 expenditure**

Commenting on developments during Q1 FY27 and to date, Bio-Gene’s Managing Director & CEO, Tim Grogan, said:

“Following completion of our recent capital raise from existing shareholders and new investors, Bio-Gene has been executing on our plans to undertake the remaining studies required to complete the first regulatory submission in Australia for Flavocide, and to reach this important company milestone as soon as possible. We are also very pleased to see strong interest in Qcide from our partners in Japan as we work to finalise arrangements for our first release of Qcide in the Japanese household nuisance insect market.

“This update reports on several areas of important technical progress at Bio-Gene, including tick efficacy data created by Purdue University and expansion of our IP platform. Based on my recent travel to Japan and the US and conversations with pest control industry professionals in those markets, it is very exciting to see the growing interest in new insecticidal products derived from

nature and that have a new mode of action. The international relevance of Bio-Gene's products in development continues to increase."

Development of Qcide for use in Japan against household nuisance insects

Bio-Gene is working with Sumitomo Corporation and Nakashima Trading Co. on the opportunity to develop and market a range of insecticide products containing Qcide, for use in Japan's household nuisance insect pest market.

The parties are working on the required documentation, product planning, specifications and product development steps required to supply Qcide into Japan and to manufacture the formulated products. As these activities are currently in progress, Bio-Gene will provide an update on the anticipated timing of the first commercial order for the supply of Qcide to Sumitomo/Nakashima when the dates have been agreed by the parties.

The 16th Qcide harvest completed in north Queensland

The latest Qcide harvest was completed successfully during the quarter and analysis of the harvested oil is now underway. A portion of this harvest involved the first cut of trees planted in 2025 that will now coppice ahead of the next harvest in Q2 2027. In addition, management of the seed production area has intensified as the trees start to bud, flower and produce seed. This area will enable continuous seed production on-site for use in expansion of the plantation area to meet the anticipated demand for Qcide oil from Sumitomo/Nakashima.

As the typical period between planting a new seedling of *Eucalyptus cloeziana* and the first harvest from that plant is approximately 18 months, it is now a priority for Bio-Gene to produce more seed to enable significant future expansion of the planted areas to produce more Qcide oil.

Update on the regulatory development of Flavocide, including OECD 424 & OECD 443

The in-life phases of acute neurotoxicity (OECD 424) and extended one-generation reproductive toxicity (OECD 443) studies for Flavocide are complete and the draft preliminary reports for both studies are currently undergoing scientific and technical review prior to finalisation. This process is an important part of finalising complex regulatory studies, ensuring that the underlying data, interpretation of findings and associated conclusions are accurately and appropriately reflected in the final study reports that will be completed in the near future.

In parallel, the remaining components of the Flavocide regulatory program are underway, including the planned safety, metabolism and pharmacokinetic studies and supporting physico-chemical and stability studies.

The data from these studies will be included in the comprehensive regulatory submission being developed to support the Company's application to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the first approval of Flavocide as a new insecticidal active constituent. Based on the current study timetable and subject to completion of the remaining studies, finalisation of study reports and preparation of the regulatory dossier, Bio-Gene is targeting submission of its initial APVMA application in Q2 CY2027.

Bio-Gene's MD & CEO in Japan and the US

During October 2026, Tim Grogan visited Japan and the US to meet with Bio-Gene's current and potential commercial partners and to attend J Agri Expo in Tokyo, Japan and Pest World in Dallas, Texas, USA. Both of these large meetings attracted the key innovators, suppliers and distributors of pest control products in these major markets.



**Meeting with distributors at the
J Agri Expo in Tokyo**



**Pest World was held in Dallas, TX and was
attended by approx. 5,000 pest management
professionals**

Flavocide tick efficacy data published in peer-reviewed journal

Subsequent to quarter end, Bio-Gene announced¹ the publication of research conducted by Purdue University in the peer-reviewed journal Ticks and Tick-borne Diseases. The study assessed the contact efficacy and residual activity of a prototype Flavocide formulation against *Ixodes scapularis*, commonly known as the deer tick, a major vector of Lyme disease.

Under laboratory conditions, the formulation achieved greater than 90% mortality of tick nymphs at 24 hours after exposure and greater than 70% mortality for up to four weeks in residual efficacy testing.

The journal article noted that: *“These findings indicate that Flavocide (in the prototype formulation) retains activity for multiple weeks under laboratory conditions, suggesting potential for extended tick control in field applications. This justifies further studies to evaluate formulation performance at lower AI concentration under laboratory conditions first, then, if confirmed, in the field.”*

This research was conducted under a vector control program funded by the US Centers for Disease Control and Prevention.

¹ See: [BGT Tick Announcement – 7 October 2026](#)

Intellectual property update

During the quarter, Bio-Gene received grants and notices of allowance for the following patent families and countries:

- Flavocide use in combination in pest management – USA, China & South Africa, granted.
- Flavocide method for control of pests (aphids) – Australia & China, granted.
- Flavocide control of resistant pests – USA & New Zealand, allowed.

These patents further strengthen Bio-Gene's intellectual property position for the use of Flavocide against a range of pests in crop and non-crop uses. These grants and allowances are aligned with the Company's commercialisation strategy, with intellectual property assets for products to be licensed to industry partners in crop, public health and consumer pest management markets.

Fundraising Activities

Completion of Placement and SPP underwriting

During the quarter, Bio-Gene completed the second tranche of its Placement and the SPP underwriting following shareholder approval at the Extraordinary General Meeting held on 5 August 2026. Completion brought total gross proceeds from the Placement and SPP to approximately \$3.275 million before costs, including funds raised in the previous quarter.

The Company issued 51,980,000 ordinary shares on completion. It also issued 69,221,150 options to Placement, SPP and SPP underwriting participants and the Placement lead manager, exercisable at \$0.035 and expiring on 15 October 2027.

The capital raising supports the remaining Flavocide safety studies required for the Company's initial Australian regulatory application, increased Qcide® production, product development and commercial partnering activities, strategic projects and working capital.

R&D tax incentive received

After quarter end, Bio-Gene received a \$343,000 R&D tax incentive relating to eligible expenditure incurred during FY26. The refund supports the development of Flavocide and Qcide and relates to eligible R&D expenditure.

Financial Update

Bio-Gene had a cash balance of \$2,103,000 as at 30 September 2026. The \$343,000 R&D tax incentive was received after this date and is therefore excluded from the quarter-end cash balance.

Payments to related parties for the quarter were \$197,617, comprising Director fees and statutory superannuation contributions to executive and non-executive directors.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

To subscribe to Bio-Gene's announcements and other forms of email communication, please visit [this page](#) of our website.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN

32 071 735 950

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(612)	(612)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(218)	(218)
(f) administration and corporate costs	(350)	(350)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	12	12
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	162	162
1.8 Other (GST Refund)	40	40
1.9 Net cash from / (used in) operating activities	(966)	(966)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,215	1,215
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(86)	(86)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	Net cash from / (used in) financing activities	1,129	1,129

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,940	1,940
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(966)	(966)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,129	1,129
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	2,103	2,103

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	39	388
5.2	Call deposits	2,064	1,551
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,103	1,940

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	198
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Note 6.1 - payments totalling **\$197,617** were made to related parties and their associates during the quarter.

This aggregate amount is comprised entirely of gross remuneration paid on a cash basis during the period, consisting of:

- **\$48,530** for Non-Executive Director fees and statutory superannuation contributions.
- **\$149,087** for Executive Director salaries and statutory superannuation contributions.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(966)
8.2	Cash and cash equivalents at quarter end (item 4.6)	2,103
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	2,103
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.18
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

30 October 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.